TaiMed Biologics Inc. (TPEX:4147)
Taiwan
· Delayed Price · Currency is TWD 49.40
+1.35 (2.81%)
Apr 29, 2026, 1:30 PM CST
TaiMed Biologics Revenue
In the year 2025, TaiMed Biologics had annual revenue of 611.35M TWD with 0.19% growth. TaiMed Biologics had revenue of 149.90M in the quarter ending December 31, 2025, with 2.83% growth.
Revenue
611.35M
Revenue Growth
+0.19%
P/S Ratio
21.47
Revenue / Employee
n/a
Employees
n/a
Market Cap
13.13B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 611.35M | 1.19M | 0.19% |
| Dec 31, 2024 | 610.16M | 118.39M | 24.07% |
| Dec 31, 2023 | 491.78M | -71.23M | -12.65% |
| Dec 31, 2022 | 563.01M | 149.57M | 36.18% |
| Dec 31, 2021 | 413.44M | -309.04M | -42.78% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EirGenix | 1.01B |
| Locus Cell | 12.74M |
| Ever Supreme Bio Technology | 1.02B |
| Polaris Group | 40.60M |
| Medigen Vaccine Biologics | 613.17M |
| Tanvex BioPharma | 400.97M |
| AP Biosciences | 32.25M |
| CHO Pharma | 1.43M |